Genprex

Category: Press Releases

Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019

Company Placing Priority on Investor Engagement with New Website, Email Updates

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 12, 2018– Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019, spearheaded by the launch of an innovative corporate website with more robust investor resources, including the company’s presentations, stock charts and integrated quotes, SEC filings, news, media coverage, and tailored email newsletters, among other advanced communication tools….

Read More

Genprex to Present at the 11th Annual LD Micro Main Event

Presentation Wed., Dec. 5, 2018, at 10:30 a.m. PST

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 3, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that its Chairman and Chief Executive Officer, Rodney Varner, will present at the 11th annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel in Los Angeles, CA….

Read More

Genprex Recognized as Finalist in Technology Innovation Category for Fierce Innovation Awards

AUSTIN, TX, November 29, 2017 – Genprex, Inc., a clinical stage gene therapy company, announced today that is has been selected as a finalist in this year’s Fierce Innovation Awards: Life Sciences Edition brought to you by the publisher of FierceBiotech and FiercePharma. Genprex was recognized as a finalist in the Fierce Technology Innovation Award category….

Read More

Genprex Provides Clinical and Corporate Update for Third Quarter 2018

AUSTIN, Texas–(BUSINESS WIRE)–Nov. 20, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update, and the filing of quarterly results for the third quarter ended September 30, 2018 on Form 10-Q with the Securities and Exchange Commission….

Read More

Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 30, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN, as the Company’s Vice President of Clinical Operations. In this role, Ms. Stevens joins the Cambridge office to contribute in supporting various clinical development programs for the Company’s immunogene therapy, Oncoprex™, which is currently being evaluated in clinical and preclinical studies at MD Anderson Cancer Center for the treatment of non-small cell lung cancer (NSCLC)….

Read More

Genprex to Present at Upcoming Investor and Industry Conferences

AUSTIN,Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 1, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that the management team will present at the following upcoming investor and industry conferences:

Event: The MicroCap Conference
Date: October 2, 2018
Time: 12:00 PM EDT
Location: New York, NY
Presenter: Rodney Varner, Chairman and CEO

Event: BIO Investor Forum
Date: October 18, 2018
Time: 9:30 AM PDT
Location: San Francisco, CA
Presenter: Dr….

Read More

Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program

AUSTIN, Texas & CAMBRIDGE, Mass. & FARGO, N.D.–(BUSINESS WIRE)–Sep. 27, 2018– Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex™ for the treatment of non-small cell lung cancer….

Read More

Genprex CEO Updates Investors on Recent $10M Capital Raise and Progress of Oncoprex

…AUSTIN, Texas & CAMBRIDGE, Mass.–Sept. 6, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, updates Proactive Investors on company operations in the last few months, notably raising $10 million to be used toward continuing the company’s clinical trial of Oncoprex.

Read More

Genprex Amends Options to License Additional Cancer Fighting Technologies from the University of Texas MD Anderson Cancer Center

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 28, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into amendments with The University of Texas MD Anderson Cancer Center (MD Anderson) to extend the terms of two option agreements between Genprex and MD Anderson pertaining the use of TUSC2, the active agent in Genprex’s lead product candidate Oncoprex, in combination with immunotherapies and the development and the use of biomarkers to predict patient response to TUSC2 therapy….

Read More

Genprex to Present at Upcoming Investor Conferences

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 21, 2018– Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that company management will present at the following upcoming investor and industry conferences:

Event: H.C. Wainwright 20th Annual Global Investment Conference
Date: September 6, 2018
Time: 5:30 PM EDT
Location: New York, NY
Presenter: Dr….

Read More